Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03542266 · ClinicalTrials.gov registry record · Phase 2
CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma
A Phase 2 study, sponsored by Weill Medical College of Cornell University.
- Completed
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT03542266 is a Phase 2 study that has completed, run by Weill Medical College of Cornell University. The registered enrollment target is 21 participants.
The verdict
NCT03542266, a Phase 2 study, has completed, sponsored by Weill Medical College of Cornell University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis.
Interventions
- DRUG CC-486 Administration
- DRUG CHOP Administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2018-06-01 |
| Est. Completion | 2022-07-25 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03542266
The ClinicalTrials.gov registry entry for NCT03542266 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which CC-486 Administration is the first listed.
NCT03542266 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03542266 about?
NCT03542266 is a clinical study titled "CC486-CHOP in Patients With Previously Untreated Peripheral T-cell Lymphoma". This is a phase II, multi-center study to determine the efficacy and safety of first-line CC-486 plus CHOP in patients with PTCL who have received no prior systemic therapy. The study has a sample size of 20, and follows two-stage minimax design for primary efficacy analysis.
What is the current status of trial NCT03542266?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2018-06-01. Estimated completion is 2022-07-25.
What interventions are being tested in trial NCT03542266?
The interventions under investigation include: CC-486 Administration (DRUG), CHOP Administration (DRUG).
Who is sponsoring clinical trial NCT03542266?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.